Ocular Therapeutix Q1 net loss $88.6M; cash $666.7M; AXPAXLI NDA on track with SOL-1 data

OCULAR THERAPEUTIX, INC

2026-Q1 EPS reported -$0.40 revenue$10,785,000

Net loss $88.6M ($0.40 per share) vs $64.1M ($0.38) in Q1 2025; revenue $10.8M, up 0.8%.
Cash $666.7M as of March 31, 2026; runway into 2028 excluding full AXPAXLI commercialization costs.
AXPAXLI NDA for wet AMD on track based on SOL-1 Week 52 data; subject to FDA discussions; 505(b)(2) pathway may shorten review.
SOL-1 positive: superior visual outcomes (74.1% maintained vision at Week 36 vs 55.8% aflibercept); p=0.0006 primary endpoint.
SOL-R non-inferiority trial on track for topline 1Q 2027; HELIOS-3 ongoing; Investor Day June 17, 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

OCULAR THERAPEUTIX, INC reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, Ocular Therapeutix, Inc. announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

OCULAR THERAPEUTIX, INC filing history →

Source: SEC EDGAR

accession 0001104659-26-055241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.